Company profile for Biostax

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Biostax is a developer and marketer of pharmaceutical, biotechnology, and MedTech products that have a well-defined path to market. Biostax has deep expertise and strong partnerships in the fields of autoimmunity and immune restoration and is able to deliver solutions today for people living with autoimmunity, chronic inflammation, infection, and cancer. The company is focused on driving the development and commercialization o...
Biostax is a developer and marketer of pharmaceutical, biotechnology, and MedTech products that have a well-defined path to market. Biostax has deep expertise and strong partnerships in the fields of autoimmunity and immune restoration and is able to deliver solutions today for people living with autoimmunity, chronic inflammation, infection, and cancer. The company is focused on driving the development and commercialization of proprietary mechanisms to prevent, intercept, and improve these diseases at affordable costs.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1317 Edgewater Dr. Suite 4882 Orlando, Florida 32804
Telephone
Telephone
+1 8883919355
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

IPhEB Russia

Not Confirmed

envelop Contact Supplier

IPhEB Russia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/difgen-pharmaceuticals-and-aveva-drug-delivery-systems-lead-us-technology-transfer-and-platform-development-collaboration-for-multi-indication-immune-restoration-therapy-with-active-ind-programs-and-phase-2b3-authorization-in-p-302724179.html

PR NEWSWIRE
25 Mar 2026

https://www.globenewswire.com/news-release/2025/02/21/3030465/0/en/Biostax-Corp-Announces-Voluntary-Delisting-from-OTC-Pink-Market-and-SEC-Deregistration.html

GLOBENEWSWIRE
21 Feb 2025

https://www.globenewswire.com//news-release/2023/11/15/2781140/0/en/Biostax-Announces-a-Director-Appointment-of-Influential-Business-Leader-Craig-Suro.html

GLOBENEWSWIRE
15 Nov 2023

https://www.globenewswire.com//news-release/2023/11/02/2772529/0/en/Biostax-Announces-the-Appointment-of-Ms-Mary-Clay-Caperton-to-its-Board-of-Directors.html

GLOBENEWSWIRE
02 Nov 2023

https://www.globenewswire.com//news-release/2023/10/24/2765720/0/en/Biostax-Announces-FINRA-Approval-for-Name-and-Ticker-Symbol-Change-Signals-Entry-into-Global-Substance-Abuse-Commercial-Markets-and-Pioneering-HIV-Treatment.html

GLOBENEWSWIRE
24 Oct 2023

https://www.globenewswire.com//news-release/2023/08/29/2733500/0/en/Biostax-Corp-Signs-Collaboration-Agreement-with-Immgenuity-Inc-to-Pursue-Remission-in-HIV.html

GLOBENEWSWIRE
29 Aug 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty